Cross-Sector entity
Adalimumab is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is markets: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 4 original sources each.
2 verified stories tracked
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Adalimumab is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is markets: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 4 original sources each. DelveInsight appears in 2 tracked Cross-Sector stories from February 19, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DelveInsight. Shared-story counts are live from our verified record — not editorial picks.
The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Source: weeklyvoice.com · admin (in)
